Resource Type

Journal Article 824

Conference Videos 49

Conference Information 3

Year

2024 4

2023 54

2022 83

2021 132

2020 83

2019 64

2018 48

2017 47

2016 30

2015 33

2014 32

2013 38

2012 32

2011 30

2010 21

2009 36

2008 22

2007 29

2006 5

2005 4

open ︾

Keywords

COVID-19 66

SARS-CoV-2 28

fuel cell 13

hepatocellular carcinoma 10

immunotherapy 10

Coronavirus disease 2019 7

cancer 7

solar cell 6

control 5

hematopoietic stem cell transplantation 5

hydrogen energy 5

prognosis 5

stem cell 5

cadmium (Cd) 4

cell proliferation 4

coronavirus disease 2019 (COVID-19) 4

lung cancer 4

microbial fuel cell 4

solid oxide fuel cell 4

open ︾

Search scope:

排序： Display mode:

Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphomaupon anti-CD19 chimeric antigen receptor T therapy

Frontiers of Medicine 2023, Volume 17, Issue 4,   Pages 699-713 doi: 10.1007/s11684-022-0972-8

Abstract: Anti-CD19 chimeric antigen receptor (CAR)-T cell therapy has achieved 40%–50However, the underlying mechanism of alterations in the tumor microenvironments resulting in CAR-T cellA multi-center phase I/II trial of anti-CD19 CD28z CAR-T (FKC876, ChiCTR1800019661) was conducted.functions of CAR-T cells, leading to CAR-T cell therapy failure and disease progression in DLBCL.Immunosuppressive tumor microenvironments persisted before CAR-T cell therapy, during both cell expansion

Keywords： anti-CD19 chimeric antigen receptor T     immunotherapy     diffuse large B cell lymphoma     tumor microenvironment    

HTML PDF Collect

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse largeB-cell lymphoma in Chinese patients

Frontiers of Medicine 2022, Volume 16, Issue 2,   Pages 285-294 doi: 10.1007/s11684-021-0843-8

Abstract: Anti-CD19 chimeric antigen receptor (CAR) T cell therapy has shown impressive efficacy in treating B-cellA single-center phase I dose-escalation study was conducted to evaluate the safety and efficacy of Tcells transduced with CBM.CD19 CAR, a second-generation anti-CD19 CAR bearing 4-1BB costimulatory molecule, for the treatment of patients with refractory diffuse large B-cell lymphoma (DLBCL).Ten heavily treated patients with refractory DLBCL were given CBM.CD19 CAR-T cell (C-CAR011) treatment

Keywords： CAR-T cell therapy     refractory diffuse large B-cell lymphoma     cytokine release syndrome     dose-limiting    

HTML PDF Collect

involvement may affect the survival of patients with relapsed or refractory non-Hodgkin lymphoma after chimericantigen receptor T cell therapy

Lili Zhou, Ping Li, Shiguang Ye, Xiaochen Tang, Junbang Wang, Jie Liu, Aibin Liang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 786-791 doi: 10.1007/s11684-020-0751-3

Abstract: Factors associated with complete and durable remissions after anti-CD19 chimeric antigen receptor T (response, overall survival (OS), and progression-free survival (PFS) in patients with r/r NHL treated with anti-CD19infiltration significantly and negatively affected OS and PFS in patients with r/r NHL treated with anti-CD19CAR-T cell therapy.Thus, anti-CD19 CAR-T cell therapy may improve the prognosis of patients with BM infiltration.

Keywords： anti-CD19 chimeric antigen receptor T cell     soft tissue     bone marrow     relapsed or refractory non-Hodgkin    

HTML PDF Collect

Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantlecell lymphoma

Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 811-815 doi: 10.1007/s11684-020-0740-6

Abstract: Chimeric antigen receptor (CAR) T-cell therapy has emerged as a novel treatment modality for r/r non-HodgkinHowever, long-term safety and tolerability associated with CAR T-cell therapy are not defined well, especiallypatient with r/r MCL with 48-month duration of follow-up who achieved long-term remission after CAR T-cellCAR T-cell-related toxicities were also mild and tolerated well even in this elderly patient.This report suggested that CAR T-cell therapy is a promising treatment modality for patients with MCL

Keywords： anti-CD19 chimeric antigen receptor T cells     mantle cell lymphoma     relapsed or refractory     long-term follow-up    

HTML PDF Collect

A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma

Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 711-725 doi: 10.1007/s11684-020-0808-3

Abstract: Chimeric antigen receptor T (CAR-T) cells were introduced as a treatment for these patients.achieved complete remission after receiving the CD19 CAR-T cell therapy.Other than the CD19-targeted CAR-T, the novel target antigens, such as CD20, CD22, CD30, and CD37, whichTherefore, optimizing the structure of CAR, creating new drugs, and combining CAR-T cell therapy withthe toxicity in patients with lymphoma after the CAR-T cell therapy.

Keywords： chimeric antigen receptor T (CAR-T) cell     lymphoma     cytokine release syndrome (CRS)     immune effector cell-associated    

HTML PDF Collect

Chimeric antigen receptor T cell therapies for acute myeloid leukemia

Bin Gu, Jianhong Chu, Depei Wu

Frontiers of Medicine 2020, Volume 14, Issue 6,   Pages 701-710 doi: 10.1007/s11684-020-0763-z

Abstract: Abstract Chimeric antigen receptor T cell (CAR T) therapies have achieved unprecedented efficacy in B-cellAllogeneic hematopoietic stem cell transplantation could be an effective therapy because of the graft-versus-leukemiaAlthough the identification of an ideal target antigen for AML is challenging, CAR T therapy remainsIn this review, we focus on the most recent and promising advances in CAR T therapies for AML.

Keywords： acute myeloid leukemia     CAR T     immunotherapy    

HTML PDF Collect

Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy

Zhao Zhang, Jun Jiang, Xiaodong Wu, Mengyao Zhang, Dan Luo, Renyu Zhang, Shiyou Li, Youwen He, Huijie Bian, Zhinan Chen

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 57-68 doi: 10.1007/s11684-019-0683-y

Abstract: In recent years, the development of tumor immunotherapy especially chimeric antigen receptor T (CAR-TEpidermal growth factor receptor variant III (EGFRvIII) is a tumor-specific mutation expressed in variousThus, EGFRvIII is a potential antigen for targeted lung cancer therapy.cell lines.The proliferation of CAR-T cells were induced by cytokine and specific antigen in vitro.

Keywords： chimeric antigen receptor T cells     epidermal growth factor receptor     lung cancer     immunotherapy     tumor immunolog    

HTML PDF Collect

Engineered T Cell Therapies from a Drug Development Viewpoint Review

Fang Chen, Joseph A. Fraietta, Carl H. June, Zhongwei Xu, J. Joseph Melenhorst, Simon F. Lacey

Engineering 2019, Volume 5, Issue 1,   Pages 140-149 doi: 10.1016/j.eng.2018.11.010

Abstract: For example, T cells can be genetically modified to express chimeric antigen receptors (CARs), endowingAnti-CD19 chimeric antigen receptor T cells (CART19) have demonstrated a remarkable degree of clinicalThe process of developing CART19 essentially follows the conventional “one gene, one drug, onejoining forces to commercialize this new category of “living drugs,” it is useful to use CART19We believe that the success of CART19 will lead to the development of other engineered T cell therapies

Keywords： Engineered T cell therapies     Chimeric antigen receptor     Drug development process     Biomarkers     CAR19     CART19    

HTML PDF Collect

Tumor-derived exosomes induce initial activation by exosomal CD19 antigen but impair the function ofCD19-specific CAR T-cells via TGF-β signaling

Frontiers of Medicine doi: 10.1007/s11684-023-1010-1

Abstract: Tumor-derived exosomes induce initial activation by exosomal CD19 antigen but impair the function ofCD19-specific CAR T-cells via TGF-β signaling

Keywords： exosomes induce activation     impair function CD19     exosomal CD19 antigen    

HTML PDF Collect

CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a

Frontiers of Medicine 2022, Volume 16, Issue 3,   Pages 322-338 doi: 10.1007/s11684-021-0901-2

Abstract: To date, six chimeric antigen receptor T cell (CAR-T) therapies have been permitted for the treatmentHowever, several clinical trials of solid tumor CAR-T therapies were prematurely terminated, or theyglycosylated glycoforms of tumor-associated antigens can also minimize the off-tumor effects of CAR-TTn, T, and sialyl-Tn antigens have been reported to be involved in tumor progression and metastasis,how underglycosylated antigens emerge and then detail the latest advances in the development of CAR-T-based

Keywords： cancer immunotherapy     chimeric antigen receptor     solid tumors     tumor-associated antigen     glycosylation     O-glycans     adoptive cell therapy    

HTML PDF Collect

Adoptive cell transfer therapy for hepatocellular carcinoma

Renyu Zhang, Zhao Zhang, Zekun Liu, Ding Wei, Xiaodong Wu, Huijie Bian, Zhinan Chen

Frontiers of Medicine 2019, Volume 13, Issue 1,   Pages 3-11 doi: 10.1007/s11684-019-0684-x

Abstract: The antitumor activities of adoptive cell transfer therapy (ACT), such as strategies based on tumor-infiltratingCurrently, chimeric antigen receptor T-cell (CAR-T) immunotherapy has achieved numerous breakthroughshematological malignancies, including relapsed or refractory lymphoblastic leukemia and refractory large B-cellThe clinical results of CAR-T immunotherapy for HCC that could be obtained at present are limited.Some published studies have demonstrated that CAR-T could inhibit tumor growth and cause severe side

Keywords： adoptive cell transfer therapy     hepatocellular carcinoma     T cell     chimeric antigen receptor     immunotherapy    

HTML PDF Collect

Emerging immunological strategies: recent advances and future directions

Frontiers of Medicine 2021, Volume 15, Issue 6,   Pages 805-828 doi: 10.1007/s11684-021-0886-x

Abstract: New approaches that promote anti-tumor immunity have recently been developed, such as small molecules, bispecific antibodies, chimeric antigen receptor T cell products, and cancer vaccines.Bispecific antibodies, which bind two different antigens or one antigen with two different epitopes,Chimeric antigen receptor T cell products and cancer vaccines have also been investigated.

Keywords： cancer immunotherapy     bispecific antibodies     small molecules     chimeric antigen receptor T therapy     cancer    

HTML PDF Collect

Development of oncolytic virotherapy: from genetic modification to combination therapy

Qiaoshuai Lan, Shuai Xia, Qian Wang, Wei Xu, Haiyan Huang, Shibo Jiang, Lu Lu

Frontiers of Medicine 2020, Volume 14, Issue 2,   Pages 160-184 doi: 10.1007/s11684-020-0750-4

Abstract: Oncolytic virotherapy (OVT) is a novel form of immunotherapy using natural or genetically modified viruses to selectively replicate in and kill malignant cells. Many genetically modified oncolytic viruses (OVs) with enhanced tumor targeting, antitumor efficacy, and safety have been generated, and safety have been genetically modified, and some of which have been assessed in clinical trials. Combining OVT with other immunotherapies can remarkably enhance the antitumor efficacy. In this work, we review the use of wild-type viruses in OVT and the strategies for OV genetic modification. We also review and discuss the combinations of OVT with other immunotherapies.

Keywords： immunotherapy     oncolytic virus     genetic modification     immune checkpoint blockade     chimeric antigen receptorT cell    

HTML PDF Collect

Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecificantibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic

Frontiers of Medicine 2022, Volume 16, Issue 1,   Pages 139-149 doi: 10.1007/s11684-021-0835-8

Abstract: The CD19-targeting bispecific T-cell engager blinatumomab has shown remarkable efficacy in patients withBlinatumomab and A-319 are CD3/CD19 bispecific antibodies with different molecular sizes and structures, and A-2019 is a novel CD3/CD19/CD20 trispecific antibody with an additional anti-CD20 function.positive T cells, enhancing T-cell function, mediating B-cell depletion, and eventually inhibiting tumorin cells missing CD19, suggesting its potential function against CD19 weak or negative CD20 positive

Keywords： B-cell acute lymphoblastic leukemia     bispecific antibody     trispecific antibody     CD19     CD20    

HTML PDF Collect

Quality Control and Nonclinical Research on CAR-T Cell Products: General Principles and Key Issues Review

Yonghong Li, Yan Huo, Lei Yu, Junzhi Wang

Engineering 2019, Volume 5, Issue 1,   Pages 122-131 doi: 10.1016/j.eng.2018.12.003

Abstract:

Adoptive cell therapy using chimeric antigen receptor T (CAR-T) cells, which is a promising cancerCAR-T cells are genetically modified T cells that can specifically recognize tumor specific antigensAt present, exciting results are being achieved in clinical applications of CAR-T cells for patientscell products are expected to be submitted in future.cell products based on their product characteristics and on relevant guidelines for gene and cell therapy

Keywords： Chimeric antigen receptor T cells     Quality control     Nonclinical research     Safety     Efficacy     Clinical    

HTML PDF Collect

Title Author Date Type Operation

Immunosuppressive tumor microenvironment contributes to tumor progression in diffuse large B-cell lymphomaupon anti-CD19 chimeric antigen receptor T therapy

Journal Article

Phase I study of CBM.CD19 chimeric antigen receptor T cell in the treatment of refractory diffuse largeB-cell lymphoma in Chinese patients

Journal Article

involvement may affect the survival of patients with relapsed or refractory non-Hodgkin lymphoma after chimericantigen receptor T cell therapy

Lili Zhou, Ping Li, Shiguang Ye, Xiaochen Tang, Junbang Wang, Jie Liu, Aibin Liang

Journal Article

Chimeric antigen receptor T-cell therapy: a promising treatment modality for relapsed/refractory mantlecell lymphoma

Ping Li, Ningxin Dong, Yu Zeng, Jie Liu, Xiaochen Tang, Junbang Wang, Wenjun Zhang, Shiguang Ye, Lili Zhou, Alex Hongsheng Chang, Aibin Liang

Journal Article

A giant step forward: chimeric antigen receptor T-cell therapy for lymphoma

Houli Zhao, Yiyun Wang, Elaine Tan Su Yin, Kui Zhao, Yongxian Hu, He Huang

Journal Article

Chimeric antigen receptor T cell therapies for acute myeloid leukemia

Bin Gu, Jianhong Chu, Depei Wu

Journal Article

Chimeric antigen receptor T cell targeting EGFRvIII for metastatic lung cancer therapy

Zhao Zhang, Jun Jiang, Xiaodong Wu, Mengyao Zhang, Dan Luo, Renyu Zhang, Shiyou Li, Youwen He, Huijie Bian, Zhinan Chen

Journal Article

Engineered T Cell Therapies from a Drug Development Viewpoint

Fang Chen, Joseph A. Fraietta, Carl H. June, Zhongwei Xu, J. Joseph Melenhorst, Simon F. Lacey

Journal Article

Tumor-derived exosomes induce initial activation by exosomal CD19 antigen but impair the function ofCD19-specific CAR T-cells via TGF-β signaling

Journal Article

CAR T cells redirected against tumor-specific antigen glycoforms: can low-sugar antigens guarantee a

Journal Article

Adoptive cell transfer therapy for hepatocellular carcinoma

Renyu Zhang, Zhao Zhang, Zekun Liu, Ding Wei, Xiaodong Wu, Huijie Bian, Zhinan Chen

Journal Article

Emerging immunological strategies: recent advances and future directions

Journal Article

Development of oncolytic virotherapy: from genetic modification to combination therapy

Qiaoshuai Lan, Shuai Xia, Qian Wang, Wei Xu, Haiyan Huang, Shibo Jiang, Lu Lu

Journal Article

Preclinical characterization and comparison between CD3/CD19 bispecific and novel CD3/CD19/CD20 trispecificantibodies against B-cell acute lymphoblastic leukemia: targeted immunotherapy for acute lymphoblastic

Journal Article

Quality Control and Nonclinical Research on CAR-T Cell Products: General Principles and Key Issues

Yonghong Li, Yan Huo, Lei Yu, Junzhi Wang

Journal Article